Stockreport

Can Zevra Therapeutics (ZVRA) Turn Clinical Momentum Into Sustainable Competitive Advantage? [Yahoo! Finance]

Zevra Therapeutics, Inc.  (ZVRA) 
PDF investigators discussed new clinical data on its approved therapy MIPLYFFA (arimoclomol) for Niemann-Pick disease type C. A unique aspect highlighted was that MIPLYFFA [Read more]